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Abstract
Currently 30 human ABC proteins are represented by full sequences in various databases, and this paper provides a brief
overview of these proteins. ABC proteins are composed of transmembrane domains (TMDs), and nucleotide binding
domains (NBDs, or ATP-binding cassettes, ABSs). The arrangement of these domains, together with available membrane
topology models of the family members, are presented. Based on their sequence similarity scores, the members of the human
ABC protein family can be grouped into eight subfamilies. At present the MDR/TAP, the ALD, the MRP/CFTR, the ABC1,
the White, the RNAseL inhibitor, the ANSA, and the GCN20 subfamilies are identified. Mutations of many human ABC
proteins are known to be causative in inherited diseases, and a short description of the molecular pathology of these ABC
gene-related genetic diseases is also provided. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
ABC (ATP binding cassette) proteins form one of
the largest protein families and its members have
been found in each kind of organism examined so
far. The aim of this review is to provide an overview
of the members of the ABC family in human. We
present the basic genetic, structural, and functional
information describing these human proteins. Since
their mutations are causative in several genetic dis-
orders, a brief summary of these phenotypes is also
provided. This snapshot re£ects the information
available at the time of compilation of the manu-
script (May, 1999), and most probably will be some-
what outdated already at the time of publication.
Due to the progress of the Human Genome Project
and to other mass sequencing e¡orts, almost half of
the known human ABC proteins were discovered
within the past two years. Partial ABC sequences
(e.g. expressed sequence tags) can also be found in
the corresponding databases, but in this review only
those human ABC proteins are discussed for which
the complete sequences are known. ABC proteins to
which independent chapters are devoted in this Spe-
cial Issue are discussed in less detail, and instead we
refer to these relevant chapters.
ABC proteins are de¢ned by the presence of the
ABC unit, a 200^250 amino acid ‘mini’ protein,
which harbors two short, conserved peptide motifs
(Walker A and Walker B), both involved in ATP
binding, and present in many other ATP utilizing
proteins as well. A third conserved sequence, diag-
nostic to the ABC unit, is located between the
Walker A and B sequences, and called ‘ABC signa-
ture’. The PROSITE sequence-related database
(http://www.expasy.ch/prosite/), which consists of bi-
ologically signi¢cant sites, patterns, and pro¢les that
help to reliably identify which known protein family
a new sequence belongs to, lists the following pat-
tern for the ABC family: ‘ABC transporters family
signature’: [LIVMFYC]-[SA]-[SAPGLVFYKQH]-
G-[DENQMW]-[KRQASPCLIMFW]-[KRNQSTA-
VM]-[KRACLVM]-[LIVMFYPAN]-F{PHY}-[LIV-
MFW]-[SAGCLIVP]-{FYWHP}-{KRHP}-[LIVM-
FYWSTA]. In this description the standard IUPAC
one-letter codes for the amino acids are used; ambi-
guities are indicated by listing the acceptable amino
acids for a given position between square parentheses
[ ]. Ambiguities are also indicated by listing the ami-
no acids that are not accepted at a given position
between a pair of curly brackets { }. Each amino
acid element in the pattern is separated from its
neighbor by a - sign.
Most ABC proteins are membrane transporters
translocating various substrates to various compart-
ments, which explains the wide spectrum of functions
ful¢lled by these proteins in di¡erent organisms. As
membrane transporters, this class of molecules con-
tains membrane-embedded, transmembrane domains
(TMDs). These transmembrane domains are usually
composed of six transmembrane (TM) helices. The
minimal structural requirement for an active ABC
transporter seems to be two TMD and two ABC
units. These may be present within one polypeptide
chain (‘full transporters’), or within a membrane-
bound multiprotein complex. In the group of active
transporters, like the multidrug resistance proteins,
the energy of ATP hydrolysis is utilized for transport
by a mechanism which involves positive cooperativ-
ity between the two ABCs, and a tight molecular
‘coupling’ of the TMDs to the ABCs. These cou-
plings ensure the transmission of the conformational
changes caused by substrate binding and by the hy-
drolysis of ATP to active transport.
Although a large number of the known ABC pro-
teins are active pumps (i.e. they can transport against
C
The proteins are grouped by subfamilies. All common names of the ABC proteins are included. Phenotype refers to the abbreviation
of the genetic disease in which mutations of the given ABC protein’s gene is involved: Stargardt macular dystrophy (STGD1); fundus
£avimaculatus (FFM); age-related macular degeneration (ARMD2); retinitis pigmentosa 19 (RP19); cone dystrophy (COD); cone-
rod-retinal dystrophy (CRD); progressive familiar intrahepatic cholestasis type 2 and type 3 (PFIC2 and PFIC3); X-linked sideroblas-
tic anemia and ataxia (XLSA/A); Dubin^Johnson syndrome (DJS); cystic ¢brosis (CF); persistent hyperinsulinemic hypoglycemia of
infancy (PHHI); adrenoleukodystrophy (ALD); cerebro-hepato-renal syndrome of Zellweger (ZWS2).
aFor domain arrangement, see Fig. 2.
bOMIM number is the reference to the OMIM (Online Mendelien Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim/) entry to
the gene (bold) or to the protein (plain).
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Table 1
An inventory of human ABC proteins, May 1999
Name Nomen-
clature
Chromo-
some
Protein
(aa)
Domain
arrangementa
Phenotype OMIM numberb
MDR/TAP subfamily
Pgp1, MDR1 ABCB1 7q21 1280 (TMD-ABC)2 171050
TAP1 ABCB2 6p21.3 686 TMD-ABC 170260
TAP2 ABCB3 6p21.3 748 TMD-ABC 170261
Pgp3, MDR3 ABCB4 7q21 1279 (TMD-ABC)2 PFIC3 171060, 602347
ABC7 ABCB7 Xq13.1-13.3 752 TMD-ABC XLSA/A 300135, 301310
M-ABC1 ABCB8 7q35-36 718 TMD-ABC
BSEP, SPGP ABCB11 2q24 1321 (TMD-ABC)2 PFIC2 603201, 601847
ALD subfamily
ALD, ALDP ABCD1 Xq28 745 TMD-ABC ALD 300100
ALDL1, ALDR ABCD2 12q11 740 TMD-ABC 601081
PXMP1, PXMP70 ABCD3 1p21-22 659 TMD-ABC ZWS2 170995
PXMP1L, P70R ABCD4 14q24.3 606 TMD-ABC 603214
MRP/CFTR subfamily
MRP1 ABCC1 16p13.12-13 1531 TMD0(TMD-ABC)2 158343
MRP2, CMOAT ABCC2 10q23-24 1545 TMD0(TMD-ABC)2 DJS 601107, 237500
MRP3, MOAT-D ABCC3 17q21.3 1527 TMD0(TMD-ABC)2
MRP4, MOAT-B ABCC4 13q31-32 1325 (TMD-ABC)2
MRP5, MOAT-C ABCC5 3q27 1437 (TMD-ABC)2
MRP6 ABCC6 16p13.1 1503 TMD0(TMD-ABC)2
CFTR ABCC7 7q31 1480 (TMD-ABC)2 CF
SUR1 ABCC8 11p15.1 1581 TMD0(TMD-ABC)2 PHHI 600509, 601820
SUR2 ABCC9 12p12.1 1549 TMD0(TMD-ABC)2 601439
ABC1 subfamily
ABC1 ABCA1 9q22-q31 2201 (TMD-ABC)2 600046
ABC3, ABC-C ABCA3 16p13.3 1704 (TMD-ABC)2 601615
ABCR ABCA4 1p22 2273 (TMD-ABC)2 STGD1/FFM,
ARMD2, RP19,
COD, CRD
601691, 248200,
153800, 601718
KIAA0822 ABCA7 17 1581 (TMD-ABC)2
White subfamily
ABC8 White ABCG1 21q22.3 638 ABC-TMD 603076
MXR1, BRCP,
ABCP
ABCG2 4q22 655 ABC-TMD 603756
OABP subfamily
RNAseLI, OABP ABCE1 4q31 599 (ABC)2 601213
ANSA subfamily
ANSA1 332 ABC
ANSA2 348 ABC
GCN20 subfamily
ABC50 ABCF1 6p21.33 807 (ABC)2 603429
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the concentration gradient of the substrate), there are
several examples deviating from this type of function.
The human GCN20 homolog, ABC50, which is a
dimeric ABC without TMDs, is most probably not
a transporter at all ; it has nuclear targeting signals
and might be involved in aminoacyl-tRNA binding.
The cystic ¢brosis transmembrane conductance reg-
ulator, CFTR, is a chloride channel, and the sulpho-
nylurea receptors, SUR1 and SUR2, are best de-
scribed as intracellular ATP sensors regulating the
permeability of potassium channels.
A highly informative website has been established
at the University of Groningen by Micheal Muller’s
group (http://www.med.rug.nl/mdl/humanabc.htm)
which is regularly updated, and at the time of prep-
aration of this review lists 39 human ABC proteins.
Twenty eight members of this list are represented by
full sequences, the sequences of the remaining 11
proteins are partial. The HUGO, Human Gene No-
menclature Committee, would like to propose a new
system of nomenclature for the ABC transporter
genes. Detailed information on the nomenclature
can be obtained electronically (http://www.gene.
ucl.ac.uk/users/hester/abc.html). Throughout this re-
view the most common names of the transporters are
used, also mentioning the synonyms.
Table 1 lists the most important data and family
relationships of the human ABC transporters cov-
ered in this review. This table is based on the list
of these proteins at the University of Groningen
website. We provide here the suggested names for
each ABC transporter, the chromosomal localization
of their genes, the number of amino acids in the gene
product and the domain arrangements. Since muta-
tions of many human ABC proteins are known to be
causative in inherited diseases, we also list here the
corresponding disease phenotypes. A large collection
of medical, physiological and molecular genetic data
Fig. 1. The dendrogram of 30 human ABC proteins represented by complete sequences in the sequence databases. The multiple align-
ment of the sequences has been generated by the ClustalW program [137] at the WWW Service of the European Bioinformatics Insti-
tute (http://www2.ebi.ac.uk/clustalw). The ‘full alignment’ mode was used with Blosum matrix method, applying the following gap
penalty values; gap open: 10, end gaps: 10, gap extension: 0.05, gap distance: 0.05.
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is available electronically (OMIM, Online Mendelien
Inheritance in Man, http://www.ncbi.nlm.nih.gov/
Omim). References to the corresponding OMIM en-
tries are also given in Table 1.
Analysis of the human ABC protein sequences re-
vealed distinct subfamilies. The dendrogram of 30
human ABC proteins represented by complete se-
quences in the database is shown in Fig. 1. The sep-
aration of four larger subfamilies ^ MRP/CFTR
(nine members), MDR/TAP (seven members), ALD
(four members) and ABC1 (four members) ^ and
four smaller groups ^ White (two members), ANSA
Fig. 2. Domain arrangement prototypes of human ABC proteins. Shaded circle with an A represents the ABC domain, vertical slabs
represent transmembrane helices within the transmembrane domains (TMD). The following con¢gurations are listed: ‘ABC’, ABC-
ABCP, TMD-ABC, ABC-TMD, (TMD-ABC)2 and TMD0(TMD-ABC)2. The upper surface of the transmembrane domains represents
extracellular orientation or facing the lumen of a cellular compartment (endoplasmic reticulum, peroxisome or mitochondrium), while
the lower surface represents intracellular (cytosolic) localization.
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(two members), and two ‘single member’ subgroups,
GCN20 (i.e. ABC50) and RNAI ^ is obvious on the
dendrogram.
Various arrangements of the TMD and ABC do-
mains can be observed among the human ABC pro-
teins (Fig. 2). The class of (TMD-ABC)2 represents
full-size transporters, and can be found in the MDR/
TAP, MRP/CFTR and ABC1 subfamilies. A third
transmembrane domain, TMD0, composed of ¢ve
TM helices, is attached to the N-terminus of several
members of the MRP/CFTR family. This is desig-
nated as TMD0(TMD-ABC)2 arrangement. A
more detailed analysis of this topology subgroup is
given in the description of MRP/CFTR family in this
Special Issue by several reviews. Two variations of
‘half transporters’ are represented among the human
ABC proteins: TMD-ABCs are in the MDR/TAP
subfamily, and four of such half transporters form
the ALD subfamily of peroxisomal transporters.
Two ABC/TMDs are found in the White subfamily.
As a general rule, full transporters are mostly located
in the plasma membrane of the host cell, while half
transporters ^ in homo- or heterodimeric form ^ are
targeted to the membranes of subcellular organelles,
like the endoplasmic reticulum, peroxisome or mito-
chondria. One representative of the ABC-ABC ar-
rangement belongs to the GNC20 subfamily and an-
other protein, with the same arrangement, is
identi¢ed as an RNAse L inhibitor. Two members
of the single ABC type (ANSA subfamily) are also
present in the human genome.
When the ABC protein classi¢cations, based on
linear amino acid sequences (Fig. 1), or considering
domain arrangements (Fig. 2) are compared, the two
schemes are not fully overlapping. This and other
observations suggest a complex evolutionary scenario
of the family, which is not the topic of the present
review. Still, throughout this chapter we emphasize
the membrane topology and domain arrangements,
as these may provide important clues to the structure
and function relationship.
A complete inventory of the yeast ABC proteins
was published earlier [1], and an inventory is also
provided in this Special Issue. These serve as useful
templates for classi¢cation of human ABC proteins.
Each kind of domain arrangement can be ¢nd
among the yeast ABC proteins, although the
TMD0(TMD-ABC)2 assembly, which is also repre-
sented by a few yeast ABCs, is not distinguished
from the (TMD-ABC)2 con¢guration in the yeast
inventory [1]. No human counterpart of the (ABC-
TMD)2 arrangement in yeast has been identi¢ed so
far. In the following sections we provide a descrip-
tion for each human ABC protein group.
2. Human ABC proteins
2.1. The MDR/TAP subfamily
Members of this subfamily are full transporters,
like MDR1, MDR3 and SisterPgp, or half transport-
ers, like TAP and TAP2, or the two mitochondrial
transporters, M-ABC1 and ABC7. The membrane
topology of MDR1 has been elucidated by epitope
insertion experiments [2,3], fully supporting the orig-
inal topology model of six TM helices in both TMDs
of the protein [4]. In the representation presented in
Fig. 3, the amino acid sequences of the MDR/TAP
family members were aligned and the hydrophobicity
plots of the aligned protein sequences were gener-
ated. The peptide segments of MDR1 spanning the
membrane bilayer are shaded in the plot of this pro-
tein. The corresponding segments, as dictated by the
multiple alignment, are also shaded in the other fam-
ily members. As seen in this ¢gure, the hydrophobic-
ity plots of the family members are similar, suggest-
ing similar membrane topologies. Still, additional
possible membrane-spanning sequences in the half
transporters are indicated by these plots.
2.1.1. MDR1/Pgp1
The multidrug transporter/P-glycoprotein (MDR1
or Pgp1) was the ¢rst human ABC protein cloned [4],
6
Fig. 3. Hydrophobicity plots of the aligned protein sequences of the members of the MDR/TAP subfamily. Peptide segments of
MDR1 spanning the membrane bilayer, determined experimentally [2,3] are shaded in the plot of MDR1. The corresponding segments
dictated by the multiple alignment are also shaded in the other family members’ plots. Hydrophobicity plots were generated as de-
scribed [66]. Proteins from the top are: MDR1, MDR3, SisterPgp, M-ABC1, Tap2, Tap1 and ABC7.
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and it is still one of the most intensively studied
proteins of the family. This special attention was
attracted by the fact that multidrug resistance of
cancer cells was found to be caused by this protein.
MDR1 is localized in the plasma membrane, on the
apical (or luminal) surface of polarized epithelial
cells. These include the brush border membrane of
intestinal cells, the biliary canalicular membrane of
hepatocytes, and the luminal membrane in proximal
tubules of kidney [5,6]. MDR1 is also present at the
pharmacological barriers of the body, e.g. at the
blood-brain barrier [7] and at the choroid plexus
[8].
The MDR1 transporter can extrude a wide range
of structurally unrelated hydrophobic toxic com-
pounds from the cell. On the basis of its localization
and its ability of vectorial transport of a range of
toxic molecules, it is suggestive that the physiological
function of MDR1 is the protection of the cells and
organism against toxic compounds [9,10]. This phys-
iological function of MDR1 was studied by a knock-
out mouse model, by disrupting one or both of the
mdr1 genes in mice [9,10]. MDR1 knockout mice are
viable and fertile, with no obvious physiological ab-
normality. However, the mice lacking both MDR1-
like transporters were found to be hypersensitive to
xenobiotic compounds. Detailed reviews of the
MDR1/Pgp structure and function are provided by
several papers in this Special Issue, and thus we refer
to these communications for further detail.
2.1.2. sPgp/BSEP and MDR3
Two members of this family, ‘the sister of P-gly-
coprotein’, sPgp or ‘bile salt export pump’ (BSEP)
and MDR3 are both involved in di¡erent types of
progressive familiar intrahepatic cholestasis, PFIC2
and PFIC3, respectively. Both MDR3 and sPgp are
full transporters with close sequence relationship to
MDR1, with 75% and 50% identical amino acids,
respectively.
sPgp was ¢rst described as a partial cDNA of a
putative porcine canalicular ABC transporter of un-
known function [11] and then the rat sPgp was
cloned by a PCR-based approach using Walker A-
and Walker B-speci¢c degenerated oligonucleotides
[12]. It was demonstrated that sPgp functions as an
ATP-dependent bile salt transporter. This protein is
expressed exclusively in the canalicular microvilli of
the liver. These data strongly support that sPgp is the
canalicular bile salt export pump of the liver [12].
The human ortholog of sPgp was identi¢ed by a
positional candidate cloning strategy, as the disease
gene of PFIC2, and termed bile salt export pump,
BSEP [13]. Chromosomal region 2q24 was identi¢ed
earlier as the locus of PFIC2 [14], characterized by
persistent neonatal cholestasis with features of amor-
phous or ¢nely ¢lamentous bile, neonatal non-specif-
ic giant cell hepatitis and later biliary cirrhosis. Mu-
tations of human sPgp/BSEP are causative in PFIC2
[13]; ten di¡erent mutations were discovered and all
are predicted to be functionally signi¢cant.
MDR3 is a phospholipid (phosphatidyl choline)
translocator [6], with a highly speci¢c expression pat-
tern in the canalicular membrane of the liver [15]. A
knockout mice model was developed to elucidate the
physiological function of the transporter, showing
that the (3/3) mice did not secrete phospholipids
into the bile and developed severe liver disease with
symptoms similar to PFIC3 [16]. PFIC3 is caused by
the reduction of biliary phospholipid secretion, with
normal bile salt concentration. This form is accom-
panied with recurrent pruritus or jaundice in the ¢rst
month of life, and then progresses to biliary cirrho-
sis. Liver histology shows portal in£ammation and
ductular proliferation in an early stage. The gene of
PFIC3 was mapped to chromosomal region 7q21.3.
Defect of MDR3 expression in PFIC3 liver was
¢rst discovered by Northern blot analysis of
mRNA, obtained from the liver tissue of a PFIC3
patient [17]. Liver sections of two PFIC3 patients
were also studied after liver transplantation by im-
munohistochemistry, using an MDR3-speci¢c poly-
clonal antibody [18]. No MDR3 staining was ob-
served, indicating the complete loss of the protein
from the canalicular membrane. Sequence analysis
of the hMDR3 transcript in the liver identi¢ed a
7 bp deletion at one of the patients, and a non-sense
mutation at a second patient. Analysis of genomic
DNA was performed to clarify the pattern of inher-
itance: the parents of both patients were found to be
heterozygous for the corresponding mutations [18].
Coexistence of PFIC3 and intrahepatic cholestasis
of pregnancy associated with an MDR3 gene defect
in a large family, was described recently [19]. A 1 bp
deletion, 1712delT, in codon 571 of the MDR3 gene
has been identi¢ed with a frameshift, and introduc-
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tion of a stop codon downstream. The mutation re-
sulted in an inactive truncated protein. Within this
family, six women had at least one typical episode of
intrahepatic cholestasis of pregnancy, resulting in the
death of fetus in three cases. Cholestasis disappeared
spontaneously and progressively after delivery. In the
four women available for study, DNA showed het-
erozygosity for the 1 bp deletion [19]. All the data
presented above clearly indicate that MDR3 is the
disease gene of PFIC3.
It is interesting to note that in spite of the high
level of sequence identity between MDR1 and
MDR3, the latter one is not implied in multidrug
resistance.
2.1.3. TAP1 and TAP2
The major histocompatibility complex (MHC) en-
codes the class I and class II families of glycoproteins
that present peptides for immunorecognition by cy-
totoxic and helper T lymphocytes, respectively. Class
II molecules associate mainly with peptides derived
from endocytosed extracellular proteins, whereas
class I molecules bind peptides generated by degra-
dation of proteins intracellularly. TAP1 and TAP2
are half ABC transporters (TM-ABC arrangement),
residents of the endoplasmic reticulum membrane.
By forming a heterodimer, TAP1/TAP2 actively
transports the peptides degraded by the peptidase
complex from the cytosol into the ER lumen, where
the peptides associate with class I molecules [20,21].
The TAP1 and TAP2 genes are located in the MHC
class II region in chromosomal region 6p21.3 [22^26].
In mutant cell lines not expressing these transport-
ers, most L2-microglobulin (L2M)-class I heavy chain
complexes do not acquire peptides. Such empty com-
plexes are unstable at physiological temperature and
are ine⁄ciently transported through the Golgi com-
partment. Relatively few peptide-free class I mole-
cules reach the cell surface, where they can be stabi-
lized by exogenous class I-speci¢c peptides [27^29].
In a family from Morocco two of ¢ve children were
homozygous for a mutation in the TAP2 gene, the
expression of class I HLA proteins on the cell surface
was de¢cient, and the cytotoxicity of natural killer
cells was a¡ected [30]. Human solid tumors and cell
lines were studied for the genetic abnormalities of
TAP1 transporter [31]. In a small cell lung cancer
cell line a heterozygous mutation (R659Q) close to
the Walker B motif has been found which resulted in
the complete loss of peptide binding and antigen pre-
sentation. Interestingly, in the cell line only the mu-
tant, R659Q allele was transcribed to RNA [31].
A detailed review of the TAP proteins is provided
in this Special Issue.
2.1.4. M-ABC1 and ABC7
These two human ABC transporter proteins are
localized to the mitochondrial membrane. Both pro-
teins are ‘half transporters’ with a TMD-ABC ar-
rangement.
M-ABC1 was cloned after a systematic search for
ABC-like ESTs with the ABC signature motif of hu-
man MDR1 and the full-length cDNA was obtained
from a lymphoblastic leukemia cDNA library [32].
The protein consists of 718 amino acids and the
gene was mapped to chromosome 7q35-36. No dis-
ease genes have been mapped to this region. The
M-ABC mRNA is widely expressed in human tis-
sues. Immunostaining revealed a colocalization of
M-ABC1 protein with the mitochondria, and it was
shown that the N-terminal region of the protein con-
tains the mitochondrial targeting signal. A segment
extending form residue 1 to 55 was fused to a green
£uorescent protein; cells transfected with this fusion
cDNA construct displayed £uorescence almost exclu-
sively at the mitochondria.
In order to identify the physiological role of M-
ABC1 in the mitochondrial membrane, a double mu-
tation was introduced into the Walker A motif
(G495A, K496R). The mutant protein was tran-
siently expressed in COS-7 cells with the expectation
that the non-functional protein will show dominant
negative phenotype by forming inactive hetero- or
homodimers. Interestingly, the mutant protein was
unstable and degraded rapidly [32].
ABC7 is the other member of the mitochondrial
ABC transporter subfamily, which was also identi¢ed
¢rst as EST [33,34] then the full cDNA was cloned
independently by several laboratories [35^37]. ABC7
is a 752 amino acid protein and shares 43% identical
residues with the yeast ATM1, which has mitochon-
drial localization. Northern blot analysis detected an
approximately 3 kb ABC7 transcript in human heart,
skeletal muscle, pancreas, lung, liver, placenta, and
several cell lines, but not in brain [34]. To investigate
the subcellular targeting of hABC7, a fusion protein,
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harboring the N-terminal 135 amino acids of the
protein and the mouse dihydrofolate reductase, was
synthesized and incubated with isolated yeast mito-
chondria. The fusion protein became processed to a
shorter form, probably by the mitochondrial process-
ing peptidase during incubation with mitochondria,
and imported into the organelle [36]. ABC7 was
found in mitochondria isolated from human liver
as a 68 kDa protein, further supporting that it is
localized in this organelle after processing [36]. It is
noticeable that ABC7 was found to be highly ex-
pressed in tissues (heart, skeletal muscle, pancreas,
lung, liver and placenta, see above) which are rich
in mitochondria.
In elegant experiments it was demonstrated that
the human ABC7 can functionally complement the
deletion of yeast ATM1, thus compensating the
growth defect of the mutant yeast strain, vatm1
[36,37]. Expressing hABC7 in yeast strain, vatm1
restored the level of cytochromes and other, heme-
containing proteins. Mitochondria of the hABC7/
vatm1 yeast did not contain high level of iron, a
phenotypical characteristic of the mutant vatm1
yeast strain [36]. On the basis of these results it can
be concluded that hABC7 is the functional ortholog
of yeast ATM1, and both ABC transporters prob-
ably contribute in transporting the same substrate
across the mitochondrial inner membrane where
they function as exporters. The nature of this sub-
strate needs to be identi¢ed, but it seems likely that
these transporters play a crucial role in iron homeo-
stasis of the cell.
The human ABC7 gene has been mapped to chro-
mosome Xq13.1-q13.3 [34]. This chromosomal re-
gion has been implicated in X-linked sideroblastic
anemia and ataxia (XLSA/A) [38]. XLSA/A is a re-
cessive disorder characterized by an infantile to early
childhood onset of non-progressive cerebellar ataxia,
and mild anemia with hypochromia and microcyto-
sis. Its main feature is that iron cannot be built into
the heme so it forms deposits in the mitochondria of
the erythroblasts. This can be detected with Prussian
blue staining as ring sideroblasts.
Mutational analysis of the ABC7 gene has been
performed in an XLSA/A family and a mutation of
I400M was discovered, which segregates within the
family [37]. It was not detected in the 600 control
chromosomes. The functional consequences of the
potential XLSA/A mutation were studied in yeast:
the corresponding residue of the ATM1 protein
was replaced with methionine (V365M). Wild-type
and V365M ATM1 was expressed in yeast strain
vatm1. A pronounced di¡erence in growth rate was
observed in the presence of 10 WM FeCl3 : cells ex-
pressing the mutant form of the transporter had a
growth defect [37]. This di¡erence was maintained
only under stringent conditions (i.e. at low iron con-
centration), which may mean that the mutation is
accompanied with only partial loss of activity of
ABC7. This suggestion is in harmony with the clin-
ical picture of these patients who have only mild
anemia [37].
All known half ABC transporters function as
dimers; whether the two mitochondrial human
ABC transporters, M-ABC1 and ABC7 form a het-
erodimer with each other, remains to be determined.
The fact that ABC7 is involved in XLSA/A while the
chromosomal region of M-ABC1 was not implicated
in the disease apparently contradicts such a possibil-
ity. But ABC-M is localized to an autosome, to chro-
mosome 7, and mutations in both alleles of M-ABC1
would be needed to cause a recessive hereditary dis-
ease like XLSA/A. On the other hand, a hemizygote
(single) mutation of the ABC7 gene on chromosome
X of a male will be causative in XLSA/A. This
means that in case of a ABC7/M-ABC1 dimer with
functional mutations of the ABC7 protein would
lead to the disease phenotype much more frequently
then those in M-ABC1.
2.2. The ALD subfamily
Four half transporters with TMD-ABC arrange-
ment, ALDP, PMP70, ALDPR and PMP69, are
members of this family; they are localized to the
peroxisomal membrane and their mutant forms are
involved in di¡erent peroxisomal disorders.
2.2.1. ALDP
Adrenoleukodystrophy (ALD) is a severe X-linked
neurodegenerative disorder a¡ecting about 1/20 000
males; it is the most frequent peroxisomal disorder.
The disease is characterized by the accumulation of
unbranched saturated fatty acids with a chain length
of 24 to 30 carbons, particularly hexacosanoate
(C26), in the cholesterol esters of brain white matter,
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in the adrenal cortex and in certain sphingolipids of
brain, and also, to a lesser extent, in other places like
¢broblasts and red cell membranes. This alteration
might interfere with myelin formation in the central
nervous system and steroidogenesis in the adrenal.
Subsequent studies showed that ALD is character-
ized by an impairment of degradation of very long
chain fatty acids (VLCFAs) in the peroxisomes. Per-
oxisomes of ALD patients lack the ability to activate
VLCFAs to their CoA esthers before entering the
L-oxidation pathway. This activation step is carried
out by very long chain fatty acid-CoA synthase
(VLCFA-CoA). A¡ected males have diminished ac-
tivity of this enzyme and this defect in their L-oxida-
tion results in the accumulation of VLCFA choles-
terol esthers. The biogenesis of the peroxisomes is
not impaired.
The gene that encodes the primary biochemical
defect in ALD maps to Xq28 [39]. and encodes a
745 amino acid protein, ALDP, a half ABC trans-
porter [40]. It is a peroxisomal membrane protein
orientated toward the cytosol [41]. It has been pro-
posed that it plays a role in the import or anchoring
of the peroxisomal enzyme VLCFA-CoA synthase,
whose activity is defective [42] in ALD. The 75
kDa ALDP detected by monoclonal antibodies was
absent in several ALD patients [41].
Less than 10% of the ALD patients have detect-
able deletions in the ALD gene [40] and about 50%
of the mutations are missense mutations [42]. The
majority of the mutations appear to be unique to
each of the kindreds. A dinucleotide (AG) deletion
at position 1801^1802 in exon 5 has been observed in
seven di¡erent studies and in a total of 14 di¡erent
kindreds. This is the most frequent mutation in ALD
gene and it seems to represent a mutation hotspot
[42]. A segment of the ALD gene harboring exons 7
to 10 has been duplicated and inserted into speci¢c
locations near the pericentromeric regions of chro-
mosomes 2, 10, 16 and 22 [43]. Sequence analysis
revealed 92^96% identity indicating a recent event
of insertion into chromosome 2 some 5^10 million
years ago followed by a rapid distribution of the
duplication cassette [43].
2.2.2. PMP70
The cerebro-hepato-renal syndrome of Zellweger is
a fatal inherited inborn error, caused by de¢cient
import of peroxisomal matrix proteins. During fetal
development of Zellweger patients the lack of assem-
bly of functional peroxisomes is the physiological
background of the multi-organ defect. Mutations of
PMP70 were found in a subset of Zellweger patients
[44]; an exon-intron splice junction mutation and a
missense mutation (G17D) have been described.
2.2.3. PMP69 and ALDRP
As both ALDP and PMP70 are half ABC trans-
porters, they may form homodimers or heterodimers
with each other, or with other homologous proteins.
It has been proposed that PMP69 [45] or ALDRP
[46], two recently identi¢ed ALD-like genes, might be
such partners. PMP69 and ALDRP may act as
modi¢er proteins in determining the phenotypic var-
iations observed in ALD. Alternatively, as potential
heterodimer partners of PMP70, they might play a
role in peroxisome biogenesis.
2.3. The MRP/CFTR subfamily
The MRP-CFTR subfamily is currently the largest
in the human ABC family, consisting of nine mem-
bers.
2.3.1. MRP1
The discovery of the human multidrug resistance
associated protein (hMRP1), conferring a multidrug
resistant phenotype to tumor cells was a landmark in
our understanding of the molecular basis of multi-
drug resistance [47]. It subsequently became clear
that the majority of non-P-glycoprotein mediated
multidrug resistance is due to the overexpression of
hMRP1. The clinical importance and the functional
characteristics of this transporter are the subjects of
several reviews in the present Special Issue.
According to our current understanding, hMRP1
probably transports both hydrophobic anticancer
agents and anionic (e.g. glutathione) drug conjugates
[48^51]. Its physiological functioning may provide a
wide range of cellular xenobiotic resistance and
MRP1 plays a key function in mediating the LTC-
dependent in£ammatory response [8,52,53]. In polar-
ized epithelial cells MRP1 is routed to the basolateral
membrane [138].
When hMRP was cloned and sequenced, analysis
of its primary amino acid sequence revealed that this
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protein is more closely related to the cystic ¢brosis
transmembrane conductance regulator (CFTR) than
to MDR1. According to the original sequence anal-
ysis, MRP was predicted to contain eight+four trans-
membrane helices, each set of helices followed by an
ABC unit [47] i.e. the canonical (TMD-ABC)2 do-
main arrangement was proposed. For members of
the subfamily identi¢ed in the following years, e.g.
SUR1 and SUR2 [54,55], cMOAT [56,57], the
(TMD-ABC)2 arrangement was generally accepted,
with predicting various numbers of membrane-span-
ning helices in each TMD.
Since numerous experimental data strongly argued
against the ¢rst membrane topology model of
hMRP1 [58,59], new models were elaborated to ac-
commodate these data and to ¢nd the correct top-
ology of the MRP-related proteins. The revised
membrane topology models for hMRP1 have been
independently forwarded by two research groups
[58,60]. Bakos et al. [58] compared the amino acid
sequence of hMRP1 with two members of the ABC
protein family: the yeast cadmium resistance protein,
YCF1 [61], which seemed to be one of the closest
relatives of hMRP1; and the human CFTR, which
belongs to this ABC subfamily, and whose mem-
brane topology has been established experimentally
[62]. They found that when the CFTR and MRP
sequences were aligned, the hydrophobicity analysis
of the aligned sequences yielded a close matching of
the transmembrane segments, thus suggesting a six+
six transmembrane helix topology for hMRP1 as
well. However, hMRP1 contained an additional
N-terminal segment of about 230 amino acids which
had no counterpart in CFTR (or e.g. in MDRs), but
closely resembled the N-terminal region of YCF1.
On the basis of these hydropathy pro¢les and limited
proteolysis experiments, the highly hydrophobic
N-terminal segment of MRP1 was suggested to be
membrane embedded with ¢ve transmembrane heli-
ces.
In parallel studies, with the cloning of the murine
MRP [60] the hydropathy plots of several ABC
transporters (mouse and human MRPs, Pgp, YCF1
and rat SUR) were aligned in order to analyze the
organization of potential membrane-embedded do-
mains. It was noticed that hMRP contains an N-
terminal domain with no counterpart in Pgp, but
closely related to that in mouse MRP, YCF1 and
SUR1. Subsequent investigations of the membrane
topology of hMRP1 by epitope insertion [63,64]
and by mutation of glycosylation sites [65] fully sup-
ported the revised topology model.
On the basis of amino acid sequence comparisons
and alignments of hydrophobicity plots of all full-
size ABC transporters present in the sequence data-
base in 1997 it was concluded that common mem-
brane topology with TMD0(TMD-ABC)2 domain
arrangement distinguishes an MRP-like subfamily
within the ABC kingdom [66].
Subsequently, new members of the MRP-CFTR
subfamily have been discovered: MRP3/MOAT-D
[67,68], MRP4/MOAT-B [69], MRP5/MOAT-C [68]
and MRP6 [70].
In the study presented in Fig. 4, the amino acid
sequences of the CFTR-MRP family members were
aligned and the hydrophobicity plots of the aligned
protein sequences were calculated. This comparison
indicates that six proteins of the family (i.e. MRP1,
MRP2, MRP3, MRP6, SUR1 and SUR2) form a
subcluster within which each member possesses the
N-terminal TMD0 domain ¢rst described for MRP1.
Thus this group of MRP-like proteins are character-
ized by the TMD0(TMD-ABC)2 arrangement. The
N-terminal TMD0 domain is absent from CFTR,
MRP4 and MRP5. It is noticeable that the level of
sequence identity is the lowest in the TMD0 domain
within the TMD0(TMD-ABC)2 subcluster. How-
ever, the membrane topology, as indicated by the
hydropathy plots, is most probably similar. Interest-
ingly, recent studies of deletion mutants of MRP1,
by the removal of the full TMD0 region, indicated
that this region is neither required for the transport
function of MRP1 nor for its proper routing to the
lateral plasma membrane compartment [71].
C
Fig. 4. Hydrophobicity plots of the aligned protein sequences of the members of the MRP/CFTR family. Peptide segments of MRP1
spanning the membrane bilayer, determined experimentally [63^65] are shaded in the plot of MRP1. The corresponding segments dic-
tated by the multiple alignment are also shaded in the other family members’ plots. Hydrophobicity plots were generated as described
[66]. Proteins from the top are: MRP1, MRP3, MRP6, MRP2, SUR1, SUR2, MRP4, MRP5 and CFTR.
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2.3.2. MRP2 (cMOAT)
Mutations of the canalicular multispeci¢c organic
anion transporter, MRP2 (cMOAT) are causative in
the Dubin^Johnson syndrome (DJS). DJS is an in-
herited defect in the secretion of amphiphilic anionic
conjugates from hepatocytes into the bile. The disor-
der is predominantly characterized by conjugated hy-
perbilirubinemia, deposition of melanin-like pigment
in otherwise normal liver cells, in some cases hepa-
tomegaly and abdominal pain, prolonged retention
of sulfobromophthalein, and otherwise normal liver
function. Detoxi¢cation of many endogenous and
xenobiotic lipophilic compounds in the liver is ac-
complished by conjugation with glutathione, glucur-
onide, or sulfate moieties, resulting in negatively
charged, amphiphilic compounds that are secreted
into bile or urine. Hepatobiliary excretion of these
conjugates is mediated by cMOAT, located exclu-
sively in the canalicular membrane of the hepatocyte
[57,72].
The identi¢cation of the transport-de¢cient mutant
rat strain, TR(3), which shows chronic conjugated
hyperbilirubinemia, as found in the human Dubin^
Johnson syndrome, contributed to the functional
characterization of cMOAT [57]. Consistent with
¢ndings of defects in the homologous cMOAT gene
in rat models of hyperbilirubinemia [57,73] two dele-
tions and a missense mutation were reported in the
cMOAT gene in patients with DJS [74]. Still, several
other members of the MRP family are present in the
hepatocyte membrane, which may compensate for
the canalicular defect and result in transport of con-
jugated compounds into the blood.
2.3.3. MRP3, MRP4, MRP5 and MRP6
The physiological function of MRP3, MRP4,
MRP5 and MRP6 is not known. MRP3 (MOAT-
D) is expressed in the liver, in the colon and in
the kidney [68], and it is inducible by phenobarbital
in HepG2 cells [67]. MRP4 (MOAT-B) is widely
expressed, with a particularly high level in the pros-
tate, but it is not found in the liver [69]. MRP5
(MOAT-C) is expressed at the highest level in
skeletal muscle and at intermediate levels in kidney,
testis, heart and brain. Interestingly, only a low
abundance of the MRP5 transcript was detected in
liver [68]. MRP6 is speci¢cally expressed in liver and
kidney, and it was suggested that MRP6 is not
involved in conferring multidrug resistance to tumor
cells [70].
When compiling the data for the MRP homolog
proteins, it is important to note that two MRP-like
sequences, which are due to interesting cloning arti-
facts, are still present in various databases.
The ‘short type of multidrug resistance protein ho-
mologue’ (SMRP) was cloned from a human lung
cancer cell line [75] which encodes 946 amino acids.
The predicted protein contains two ABC domains
and only one transmembrane domain with six mem-
brane-spanning helices (ABC-TMD-ABC). Accord-
ing to a homology search the deduced sequence is
most closely related to the members of the MRP
subfamily of the ABC transporters, but the protein
is much shorter than the established members of this
group (e.g. hMRP1: 1531 aa; cMOAT: 1545 aa). On
the other hand, a conceptual translation of the pub-
lished 5P UTR sequence of SMRP cDNA revealed
that it encodes a single open reading frame (ORF)
of 189 amino acids with high sequence similarity to
the corresponding regions of the MRP family mem-
bers, and represents a segment covering four trans-
membrane helices of the ‘missing transmembrane do-
main’ of the hypothetical SMRP. On the basis of this
observation it was suggested that SMRP represents
the partial sequence of an MRP-like transporter [76].
As the full sequence of MRP5 became available [68],
it is clear now that SMRP is a partial sequence of
MRP5.
The ‘anthracycline resistance protein’ (ARA) was
also reported as a novel MRP-like ABC protein
which consists of only 453 amino acids and a domain
arrangement of TMD-ABC. The overexpression of
ARA has been ¢rst described in a drug selected leu-
kemia cell line, in which the ‘ARA gene’ was ampli-
¢ed [77]. The ARA transcript has been shown to be
co-expressed with MRP1 in a series of multidrug
resistant leukemia cell sublines [78] and its predicted
amino acid sequence was found to be closely related
to the C-terminal portion of hMRP1. The hydropho-
bicity plot constructed for ARA and aligned with
that of hMRP1 revealed that ARA contains a dele-
tion in the transmembrane region. Thus the hypo-
thetical ARA protein can not form the characteristic
six transmembrane helix TMD of ABC proteins. A
sequence alignment of the ARA cDNA revealed an
unexpected composition of this transcript. The ¢rst
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1^115 bp 5P non-coding region is identical (100%
similarity score) with the 5P end of the MRP1
cDNA. The regions coding for the N-terminal eight
amino acids of ARA and MRP1 (116^130 bp, ARA
numbering) are also identical. The remaining sequen-
ces match completely with the eight 3P exons of the
MRP6 gene ([70], and Va¤radi, unpublished).
This composition clearly indicates that the ARA
transcript is ‘put together’ from pieces of two neigh-
boring homologous genes, MRP1 and MRP6. How-
ever, these two genes are situated in opposite reading
directions on chromosome 16 (their 3P ends are sep-
arated by 9 kb). It seems plausible to suppose that
the ARA transcript resulted from an inverted and
partially deleted chromosome, or ampli¢ed chromo-
somal fragment formed in a drug selected leukemia
cell line. In the normal human genome there is no
ARA gene, ARA is most probably a non-functional
transcript of a largely rearranged tumor cell DNA.
2.3.4. SUR1 and SUR2
The sulfonylurea receptor, SUR1, is a representa-
tive of the TMD0(TMD-ABC)2 domain arrange-
ment transporters within the MRP subfamily. Sulfo-
nylureas promote insulin secretion, interact with the
sulfonylurea receptor of pancreatic L cells and inhibit
the conductance of ATP-dependent potassium chan-
nels [54]. Mutations of SUR1 has been found to
cause a rare genetic disease, persistent hyperinsuline-
mic hypoglycemia of infancy (PHHI). PHHI is due
to defective negative feedback regulation of insulin
secretion by low glucose levels, resulting in excess
insulin secretion and hypoglycemia. Most inherited
cases follow an autosomal recessive pattern, and mu-
tations of the SUR1 gene or the closely linked
KIR6.2 gene have been found in several families.
Both of these genes encode components of the po-
tassium channels responsible for glucose-regulated
insulin release [79^81].
The sulfonylurea receptor may sense changes in
ATP and ADP concentration, a¡ect K(ATP) channel
activity, and thereby modulate insulin release [82].
Data in the literature indicate that both nucleotide
binding fold regions of the sulfonylurea receptor are
required for normal regulation of L cell ATP-depend-
ent potassium channel activity and insulin secretion
[83] (for details see the review in this Special Issue).
An isoform of SUR, designated as sulfonylurea
receptor-2 (SUR2), was cloned [55] from a rat brain
cDNA library. The 5300 bp cDNA sequence encodes
a protein of 1545 amino acids that shares 68% iden-
tity with SUR1. Although the structural features of
SUR1 and SUR2 are similar, the ATP sensitivity and
pharmacological properties of the K(ATP) channel
reconstituted from SUR2 are distinct from those ob-
tained from the SUR1 [55].
2.3.5. CFTR
Cystic ¢brosis (CF) is one of the most frequent
inherited diseases with prevalence of 1 in 2500 births
within the Caucasian populations. It is an autosomal
recessive disorder a¡ecting a variety of epithelial tis-
sues. Manifestations relate not only to the disruption
of exocrine function of the pancreas but also to in-
testinal glands (meconium ileus), biliary tree (biliary
cirrhosis), bronchial glands (chronic bronchopulmo-
nary infection with emphysema), and sweat glands
(high sweat electrolyte). Infertility occurs in males
and females. The CF gene has been cloned by posi-
tional cloning and the ‘cystic ¢brosis transmembrane
conductance regulator’ protein (CFTR) was identi-
¢ed [84]. CFTR forms a cAMP activated chloride
channel and is characterized by a speci¢c domain
arrangement: TMD-ABC-R-TMD-ABC, in which
R is a regulatory domain, the main target of phos-
phorylations regulating CFTR channel activity.
Although the major mutation that results in a single
amino acid deletion (vF508) accounts for 70% of the
disease alleles, by now more than 800 disease-causing
mutations are identi¢ed (http://www.genet.sickkids.
on.ca/cftr/).
Many of these mutations can be divided into ¢ve
general classes in terms of their demonstrated or pre-
sumed molecular consequences. These are no synthe-
sis (e.g. G542X, 394delTT, 1717/G-A), a block in
processing (e.g. vF508), a block in regulation (e.g.
G551D), altered conductance (e.g. R117H) and re-
duced synthesis (e.g. A455E, 3849+10kb-T) of
CFTR [85]. Existence of at least two genetic loci
was demonstrated that could modify the severity of
the disease [86].
An alternatively spliced form of CFTR mRNA
has been identi¢ed in heart, which lacks a 30 amino
acid segment of the ¢rst cytoplasmic loop [87,88].
Expression of this cDNA in Xenopus oocytes gave
rise to robust cAMP-activated chloride currents [89].
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Evaluation of human CFTR mRNA transcripts
from epithelial and non-epithelial cells demonstrated
a CFTR cDNA containing a 260 bp insertion be-
tween CFTR exons 23 and 24. This insertion intro-
duces a premature stop codon that would result in a
protein shortened by 61 amino acids at the carboxyl
terminus [90]. Sequence analysis of intron 23 of the
gene demonstrated that the 260 bp insertion (named
exon 24a) is a part of intron 23. The exon 24a+
CFTR mRNA transcripts represented 3^16% of the
total CFTR transcripts in epithelial and non-epithe-
lial cells. These observations suggest an unexpected
plasticity of the expression of the CFTR gene, where
alternative splicing of precursor CFTR mRNA tran-
scripts permits the use of an alternative exon, derived
from a genomic segment previously believed to func-
tion as an intron [90].
Another alternative transcript, often present at
high levels, results in the in-frame deletion of exon
9 [91]. Translation of this transcript would result in a
CFTR protein missing the amino terminal portion of
the ¢rst ABC. The protein produced by the CFTR
v9 transcript is not properly processed and is not
capable of generating Cl3 conductance in response
to cAMP [91]. A unique feature of the acceptor splice
site preceding this exon is a variable length polymor-
phism within the polypyrimidine tract, in£uencing
the extent of exon 9 skipping in CFTR mRNA
[91]. The 5-thymidine (5T) variant of the intron 8
polypyrimidine tract (IVS8-T tract) is the most fre-
quent CFTR gene variant identi¢ed in men with con-
genital bilateral absence of vas deferens (CBAVD)
[92]. These patients usually have none of the other
clinical signs of classical cystic ¢brosis. This alterna-
tive splicing variant gives rise to two transcripts, one
normal with exon 9 intact and the other with in-
frame deletion of exon 9. Correlation was found be-
tween the length of the IVS8-T tract and the level of
alternatively spliced transcripts. Results from histo-
logical analysis also suggest an involvement of the
alternative transcript in the spermatogenic status of
patients, leading to a decreased number of mature
sperm forms in the tubule [93]. A signi¢cantly higher
level of transcripts lacking exon 9 was found in vas
deferens than in nasal epithelia, regardless of the
IVS8-T genotype [94]. These ¢ndings suggest that
the splicing of CFTR precursor mRNA is less e⁄-
cient in vasal epithelia, as compared to the respira-
tory epithelia. Thus, di¡erential splicing e⁄ciency
between the various tissues which express CFTR
provides one possible explanation for the reproduc-
tive tract abnormalities observed in infertile men
with CFTR gene alterations but without other clin-
ical manifestations of CF [95].
Searching for CFTR-related genes by hybridiza-
tion screening of cDNA and genomic libraries led
to the identi¢cation of several copies of CFTR
exon 9 and its £anking introns [96]. These CFTR
exon 9-related sequences were characterized and their
chromosomal localization has been determined. At
least 10 copies of this ampli¢ed CFTR exon 9 are
present in the genome. It was revealed that these
sequences are juxtapositioned with two segments of
LINE1 (long interspersed nuclear elements) sequen-
ces. LINE1s are the most abundant retrotransposons
in the human genome and LINE1 mediated trans-
duction is a potential source of genome diversity
[97]. It seems that these CFTR exon 9-related multi-
copy sequences were derived from a single retrotrans-
position event and subsequent DNA ampli¢cation.
Sequence analyses of the 647 bp CFTR gene seg-
ments revealed identity of 92^96%. An estimation,
based on the average mutation rate of the genome,
suggests that the retrotransposition event might hap-
pen 7^10 million years ago [96].
2.4. The ABC1 family
Four members of this family, ABC1, ABCR,
ABC3 and KIAA0822 are known today. They are
full-size transporters, ABC1 and ABCR are the larg-
est human ABC proteins with 2201 and 2273 amino
acids, respectively; ABC3 consists of 1704, while
KIAA0822 is composed of 1582 amino acids.
2.4.1. ABC1
The ¢rst member of the family, the mouse ABC1,
was cloned by a PCR-based strategy [98] and the
human ABC1 was identi¢ed by using sequence infor-
mation of the mouse protein [99]. Both ABC1 and
ABCR, which share 50% of identical amino acids,
contain a large cytoplasmic domain of unknown ori-
gin and function. This region harbors a short hydro-
phobic segment, which is not long enough to expand
the membrane twice, but may attach this region to
the membrane on the cytoplasmic site or form a part
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of the inner core of this globular domain. Interest-
ingly, no counterpart of the ABC1 family is present
in the yeast genome [1].
The mouse ABC1 is involved in the engulfment of
apoptotic cells by macrophages [100]. The Cenorhab-
ditis elegans structural homolog of ABC1, Ced-7, has
similar function in this invertebrate, as Ced-7 loss of
function phenotype results in impaired engulfment
[101]. ABC1 was found to generate an electroneutral
anion e¥ux when expressed in Xenopus laevis oocytes
[102], and it was also shown to play a crucial role in
macrophage interleukin-1L secretion [103]. The tis-
sue-speci¢c expression of human ABC1 has been de-
termined: the highest expression levels were detected
in placenta, liver, lung, adrenal glands and various
fetal tissues. The high level of ABC1 mRNA and
protein in fetal liver and placenta are in harmony
with the role of the transporter in clearing the apop-
totic cells by macrophages [99]. The expression of
hABC1 in monocytes/macrophages is sterol depend-
ent, it is inversely regulated by cholesterol import
and export, which may suggest that ABC1 transports
lipids in distinct cell membranes [99].
2.4.2. ABCR
ABCR is a retinal ABC transporter, which was
discovered by positional candidate cloning and it
was found to be mutated in the recessive Stargardt
macular dystrophy (STGD) [104].
The gene encoding hABCR was mapped to a 2 cM
interval at chromosome 1p21-p13, the interval previ-
ously shown by linkage analysis to harbor the STGD
gene [105]. The ¢rst several hundred bases upstream
of the transcription unit are relatively conserved be-
tween mouse and human and contain several pre-
dicted cis regulatory elements, including two Ret-4-
like elements that reportedly confer photoreceptor-
speci¢c gene expression [106,107]. ABCR expression
is found exclusively in the retinal rod photoreceptors
and the protein is localized to the rim of the rod
outer segment discs [108].
The physiological transport substrate of ABCR is
currently unknown, but it is most probably a mole-
cule or molecules playing important role in photo-
receptor homeostasis. The bovine ABCR protein has
been puri¢ed and reconstituted into liposomes and
its ATPase activity was studied with the intention
of identifying possible substrate(s) of the transporter
[109]. Forty three di¡erent hydrophobic compounds,
including MDR1 substrates, detergents and retinoids
were tested for stimulation of the ABCR-ATPase
activity. All-trans-retinal, 11-cys- and 13-cys-retinal
showed stimulation with Km values of 10^15 WM.
These data suggest that retinoids are the natural sub-
strates of ABCR [109].
Since the discovery of ABCR in 1997, it became
one of the most studied genes involved in inherited
eye diseases. Genetic eye diseases are the most com-
mon causes of blindness in the developed world and
mutations of the retina-speci¢c ABCR transporter is
responsible for several inherited eye diseases. Muta-
tions in the ABCR gene cause Stargardt disease
(STGD), and fundus £avimaculatus (FFM) [110].
ABCR mutations in heterozygous form were also
found in 16% of patients with age-related macular
degeneration (AMD) [110] and were identi¢ed in re-
cessive retinitis pigmentosa (RP19) [111], cone dys-
trophy (COD) and cone-rod dystrophy (CRD) [112].
Di¡erent combinations of ABCR mutations can give
rise to di¡erent phenotypes, a¡ecting predominantly
the macula (STGD, COD, AMD) [113], the periph-
eral retina (RP), or both (CRD) [114].
An attractive model based on the genotype/pheno-
type relationship has been elaborated [114]. Retinitis
pigmentosa 19, the most severe eye disease associated
to ABCR mutations is caused by two severe muta-
tions, e.g. frameshift due to a single base deletion
(1847delA) and splice site mutations. CRD and
STGD patients carry either two moderately severe
mutations, or a severe mutation accompanied with
a mild one on the other allele. Accordingly, no
STGD patient has been diagnosed with two severe
mutations so far. The risk of developing AMD
(which is caused by heterozygous ABCR mutations)
is related with the severity of the mutation, i.e. the
penetrance of an AMD mutation depends on the
remaining ABCR activity. The above model was sup-
ported recently by an extensive mutational study of
150 STGD families [117].
This development suggests that a gene causing a
Mendelian disorder might also play a role in complex
genetic diseases. That di¡erent ABCR mutations
cause distinct chorioretinal diseases resembles the
genotype vs. phenotype relationship observed in
cystic ¢brosis where the mutations of CFTR lead
to phenotypes ranging from the absence of vas def-
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erens in its mildest form, to severe pulmonary and
pancreatic disease.
2.4.3. ABC3
ABC3 was cloned [118] and classi¢ed as a member
of the ABC1 family. It was noticed that the C. ele-
gans protein Ced-7 is homologous to human ABC3,
not only to human ABC1 [119]. Ced-7 functions in
the engulfment of cell corpses during programmed
cell death, is broadly expressed during embryogene-
sis, and is localized to the plasma membrane. Mosaic
analysis revealed that Ced-7 functions in both dying
cells and engul¢ng cells during the engulfment proc-
ess. It was proposed that Ced-7 functions to trans-
locate molecules that mediate homotypic adhesion
between the cell surfaces of the dying and engul¢ng
cells [119]. These authors also suggested that ABC3
may be functionally similar and that the molecular
mechanism underlying cell corpse engulfment during
programmed cell death may be conserved from nem-
atodes to mammals.
2.4.4. KIAA0822
The KIAA0822 transcript was identi¢ed during a
mass sequencing project by determining the complete
sequences of 100 new cDNA clones from human
brain [120]. The gene of KIAA0822 was sequenced
as part of sequencing chromosome 17, it is located
on clone hRPK.235 I 10 (Accession number:
AC005922), with currently unknown function.
2.5. The White subfamily
The subfamily is named after the White gene of
Drosophila melanogaster and it is characterized by a
unique ABC-TM domain arrangement. The Droso-
phila White gene is involved in the transport of eye
pigment precursors and it has a historical interest:
this was the ¢rst gene ever mapped [121].
In Drosophila the subfamily consists of the White
(W), Scarlet (St), and Brown (Bw) proteins. These
are parts of a membrane-spanning permease system,
necessary for the transport of pigment precursors
into pigment cells responsible for eye color. These
half transporters dimerize to form an active trans-
porter: White dimerizes with Brown for the trans-
port of guanine and with Scarlet for the transport
of tryptophan.
Two human ABC transporter genes, belonging
to the White subfamily have been identi¢ed recent-
ly: the ABC8/hwhite mapped onto chromosome
21q22.3; the mitoxantrone resistance associated pro-
tein 1/breast cancer resistance protein/placenta-spe-
ci¢c ABC protein mapped onto chromosome 4p22.
2.5.1. White/ABC8
The human white homolog/ABC8 was identi¢ed
by two di¡erent approaches [122,123]. When creating
the transcript map of human chromosome 21, Chen
et al. [122] performed exon trapping to identify
genes, and isolated two exons encoding protein se-
quences with homology to Drosophila White. They
screened a retina library with one exon and isolated
cDNAs corresponding to the entire coding region of
the human white gene. The protein sequences of
Drosophila White and the predicted 674 amino
acid human protein share 33% identical amino acids.
By sequencing additional cDNAs and by RT-PCR
method, evidence of an alternative splicing has
been found. A short exon, encoding 12 amino acids,
corresponding to the region which serves as a linker
between the ABC and the TMD unit, is spliced out
in several cDNAs isolated from a human cDNA li-
brary [122].
Interestingly the mouse white gene transcript,
which shares 97% identical amino acids with human
white, lacks this 12 amino acid segment [123,124].
The 3P UTR of the human white gene harbors a
polymorphic site: the poly(T) region was found to
be polymorphic in the population [122]. The Droso-
phila White gene also possesses a poly(T) segment at
the 3P UTR [125], which may suggest a possible func-
tional role of this poly(T) sequence.
An alternative cloning strategy was also applied,
which involved polymerase chain reaction using de-
generated oligonucleotide primers, based on con-
served sequence motifs within the White subfamily
[123]. The human white transcript isolated by this
strategy from a Jurkat T cell cDNA library predicts
a protein of 638 amino acids. This sequence is short-
er than that identi¢ed independently; the length dif-
ference is due to the di¡erence in prediction of the
position of the translation initiation codon at the 5P
end of the transcripts.
The human white protein most probably forms
homodimer or heterodimer(s) with other half trans-
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porter(s) to create active transporter(s). The physio-
logical role of the human white gene is not known.
In general, to predict possible function on the basis
of cross-species sequence homology is very risky
within the ABC protein family, as members of the
same subfamily may transport di¡erent substrates in
di¡erent species thus ful¢lling di¡erent physiological
roles. Nevertheless, hwhite can be considered as a
positional candidate gene of several inherited dis-
eases mapped to the chromosome 21q22.3 region.
If the functional analogy holds, and human white
plays a crucial role in tryptophan and guanine up-
take, like Drosophila White, this transport system
may determine some neurotransmitter metabolic
pathways, as e.g. tryptophan is the major precursor
of serotonin. On this line of reasoning it is noticeable
that the chromosomal position of neurodegenerative
disorders, like the autosomal recessive non-syndrom-
ic deafness, DFNB8, the manic-depressive psychosis
MD1, and myoclonic epilepsy of Lafora, MELF, are
in the region where human white is mapped.
2.5.2. BCRP/MXR1/ABCP
The second member of the White subfamily was
discovered in di¡erent multidrug resistant cell lines
by two independent studies. In a human breast can-
cer subline, MCF-7/AdrVp, that shows anthracycline
resistance without the overexpression of MDR1 or
MRP1, this protein was identi¢ed as the ‘breast can-
cer resistance protein’, BCRP [126]. In a human
colon carcinoma line, S1-M1-80 with a similar
phenotype, the gene product was cloned as the
‘mitoxantrone resistance associated protein 1’,
MXR1 [127]. At the same time, a third approach,
based on searching the EST sequence database for
ABC gene products, led to the identi¢cation of the
same transcript in placenta as the ‘placenta-speci¢c
ABC gene, ABCP’ [128]. The gene was mapped to
chromosome 4q22 and encodes a protein of 655 ami-
no acids which shares 31% identity with the Droso-
phila White and 30% identity with the human white/
ABC8 protein.
It was demonstrated that a variety of drug-resist-
ant human cancer cell lines, derived by selection with
mitoxantrone, markedly overexpressed BCRP
mRNA; these cell lines included sublines of human
breast carcinoma (MCF-7), colon carcinoma (S1 and
HT29), gastric carcinoma (EPG85-257), ¢brosarco-
ma (EPF86-079), and myeloma (8226) origins. Anal-
ysis of genomic DNA from BCRP overexpressing
MCF-7/MX cells demonstrated that the BCRP
gene was ampli¢ed in these cells [129].
Several experimental data support that the protein
is involved in multidrug resistance: upon transfection
of the BCRP cDNA into drug-sensitive human
breast cancer MCF-7 cells, the cloned transfected
cells became resistant to mitoxantrone, daunorubicin
and doxorubicin, displayed diminished intracellular
accumulation of daunorubicin, and manifested an
ATP-dependent increase in the e¥ux of rhodamine
123 [126]. The results of these experiments still can
not answer the question whether this half transporter
acts as a homo- or as a heterodimer. Furthermore,
the eukaryotic ABC half transporters mostly reside
in intracellular organelle membranes, like the endo-
plasmic reticulum (TAP1/TAP2) or the peroxisome
(ALD transporter family). The cellular localization
of the multidrug transporter, belonging to the White
subfamily, remains to be determined. The multidrug
transporters MDR1/Pgp1 and MRP1 are expressed
at various tissue barriers; the high level of expression
of the white-type multidrug transporter in placenta
[128] may re£ect a similar role of this transporter at
the placental barrier.
2.6. The OABP (RNAse L inhibitor) subfamily
2.6.1. RNase L inhibitor
The 2-5A system is one of the major pathways
induced by interferon; it is composed of three enzy-
matic activities, e.g. 2-5A synthetases, 2-5A phospho-
diesterase, and RNase L. 2-5A synthetases belong to
the family of four IFN-inducible enzymes which,
upon activation by double-stranded RNA, convert
ATP into the unusual series of oligomers known as
2-5As. The 2-5A-dependent endoribonuclease L, or
RNase L, is the e¡ector enzyme of this system. Its
activation by subnanomolar levels of 2-5A leads to
the inhibition of protein synthesis by cleavage of
mRNAs. The cloning of a polypeptide inhibitor of
the 2-5A pathway, RNase L inhibitor was described
[130]. RNase L inhibitor is a regulatory protein
whose co-expression inhibits the binding of 2-5A by
the endogenous RNase L and, as a consequence, the
2-5A-dependent activation of RNase L is arrested
[130]. Although it was not noticed in the original
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paper, sequence comparisons revealed that RNase L
inhibitor is an ABC protein of 599 amino acids, pos-
sessing two ABCs and no transmembrane domain(s),
that is an ABC-ABC arrangement.
2.7. The ANSA subfamily
The multicomponent arsenite transporter system,
encoded by the ars operon of E. coli contains two
regulatory and three structural genes [131]. ArsA co-
des for an ABC-ABC dimeric ATPase, which asso-
ciates with the product of the arsB gene, an inner
membrane protein of 12 transmembrane helices.
The complex of arsA and arsB transports arsenite
and antimonite out of the bacteria. Homologs of
arsA have been identi¢ed in many bacteria (e.g.
upon whole genome sequencing), in yeast and in C.
elegans ; some of these proteins consist of two ABCs,
while others are monomeric.
2.7.1. ANSAI and ANSAII
A human arsA homolog was cloned by a PCR
strategy utilizing degenerated primers, corresponding
to regions where arsA and the C. elegans homolog
share identical amino acids [132]. The human homo-
log, hASNAI is a monomeric, single ABC ATPase of
332 amino acids. It shares 28% identical amino acids
with both ABC units encoded by arsA, 46% with the
yeast YDL100c homolog, and 54% with the C. ele-
gans homolog; these two proteins are monomeric
ABCs like hANSAI. Another human homolog,
hANSAII, has been identi¢ed recently (AF-
047469.1); the two human proteins, hANSAI and
hANSAII, are 98% identical. The two human arsA
homologs, hANSAI and hANSAII, are not listed
in the ‘human ATP binding cassette transporters’
website (http://www.med.rug.nl/mdl/humanabc.htm).
The chromosomal localizations of the genes of
hANSAI and hANSAII are not known. They form
a subfamily of single ABC domain proteins in the
human ABC family.
One of the interesting features of E. coli arsA is
that it has an allosteric activator site. Three cysteine
residues, two situated at the N-terminal, one at the
C-terminal ABC of E. coli ArsA, form a binding site,
which e¡ectively coordinates arsenite; saturation of
this e¡ector site facilitates the activity of arsA [133].
The two human arsA homologs do not possess Cys
residues in the corresponding positions, indicating
that this kind of allosteric e¡ector site is not present.
It is also noteworthy that the human arsA homologs
(hASNAI and hASNAII) are more closely related to
the arsenical pump-driving ATPases of two archaeas,
Methanobacterium thermoautotrophicum [134] and
Methanococcus jannaschii [135], with 36% identical
amino acids in both cases, than to the E. coli arsA
protein. The two archaea homologs are mono-
meric.
2.8. The GCN20 subfamily
2.8.1. ABC50
A search for new genes modulated by tumor ne-
crosis factor-K (TNF-K) in the synoviocytes has been
performed, utilizing a di¡erential display PCR to
produce cDNA fragments which correspond to
TNF-K modulated genes. One of the identi¢ed tran-
scripts encodes the ABC50 protein of 807 amino
acids, a homolog of the yeast GCN20 [136]. This
type of ABC proteins lacks transmembrane domains
and consist of two ABC units, forming an ABC-ABC
covalent dimer. The ABC50 sequence has many fea-
tures which makes this protein unique within the
human ABC kingdom: (i) it contains no transmem-
brane domain(s); (ii) it is much more hydrophilic
than other members of the family, i.e. the ratio of
charged residues in ABC50 is 36%, while it is be-
tween 18^27% for the other human ABC proteins.
Considering these characteristics it can be concluded
that ABC50 may not be a transporter. Three nuclear
localization signals: KKKR at position 73, RRKK
at position 82 and KRPK at position 564 can be
identi¢ed in the sequence. Only one member of the
subfamily is identi¢ed as of today in the human ge-
nome.
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